Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate

Archives of Pathology and Laboratory Medicine

Volumn 128, Issue 9, 2004, Pages 980-985

  Xu, Yin ^a,b   Wahner, Andrea E ^a   Nguyen, Phuong L ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA; IMATINIB; RETICULIN;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BASOPHILIA; BLAST CELL CRISIS; BLAST TRANSFORMATION; BONE MARROW; CANCER GROWTH; CANCER PATIENT; CASE REPORT; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLONAL VARIATION; FIBROSIS; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; LEUKEMIA REMISSION; LEUKOCYTOSIS; MALE; MINIMAL RESIDUAL DISEASE; MONITORING; MORPHOLOGY; PANCYTOPENIA; PHILADELPHIA 1 CHROMOSOME; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; BLAST CRISIS; BONE MARROW; CYTOGENETIC ANALYSIS; DISEASE PROGRESSION; FIBROSIS; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; PIPERAZINES; PYRIMIDINES;

EID: 4444341003     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990;247:1079-1082.
2. Gishizky ML, Witte ON. Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro. Science. 1992;256:836-839.
3. Braziel RM, Launder TM, Druker BJ, et al. Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience. Blood. 2002;100:435-441.
4. Kantarjian HM, Cortes J, O'Brien S, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood. 2002;99:3547-3553.
5. Frater JL, Tallman MS, Variakojis D, et al. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec): bone marrow histopathology and correlation with genetic status. Am J Clin Pathol. 2003;119:833-841.
6. Nguyen PL. Collection, processing, and examination of bone marrow specimens. In: Jaffe ES, Harris NL, Vardiman JW, eds. Diagnostic Hematopathology. New York, NY: Harcourt Health Sciences. In press.
7. Cohen MH, Williams C, Johnson JR, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res. 2002;8:935-942.
8. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99:1928-1937.
9. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99:3530-3539.
10. Corbin AS, La Rosee P, Stoffregen EP, Druker BJ, Deininger MW. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood. 2003;101:4611-4614.
11. Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002;16:2190-2196.
12. Hochhaus A, Kreil S, Corbin A, et al. Roots of clinical resistance to STI-571 cancer therapy. Science. 2001;293:2163.
13. Beham-Schmid C, Apfelbeck U, Sill H, et al. Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. Blood. 2002;99:381-383.
14. Yang M, Khachigian LM, Hicks C, Chesterman CN, Chong BH. Identification of PDGF receptors on human megakaryocytes and megakaryocytic cell lines. Thromb Haemost. 1997;78:892-896.
15. Chen G, Yuan SS, Liu W, et al. Radiation-induced assembly of Rad51 and Rad52 recombination complex requires ATM and c-Abl. J Biol Chem. 1999;274: 12748-12752.
16. Kharbanda S, Pandey P, Jin S, et al. Functional interaction between DNA-PK and c-Abl in response to DNA damage. Nature. 1997;386:732-735.
17. Yuan ZM, Shioya H, Ishiko T, et al. p73 Is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature. 1999;399:814-817.
18. Cortes JE, Talpaz M, Giles F, et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood. 2003;101:3794-3800.
19. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003;102:276-283.
20. Kantarjian HM, Cortes JE, O'Brien S, et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood. 2003;101:97-100.